poisar

Stocks · News reference

Iridex Announces Publication Of 2-Yr Clinical Study Demonstrating Favorable Outcomes With TLT Using MicroPulse Technology In Patients With Primary Glaucoma

Benzinga Newsdesk

Iridex Corporation (NASDAQ:IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IRIX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Iridex Corporation

    Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

    Iridex Corporation announced the publication of a two-year clinical study in the International Journal of Ophthalmology demonstrating that MicroPulse transscleral laser therapy (TLT) significantly reduces intraocular pressure and medication burden in patients with early to advanced glaucoma. The study of 84 eyes showed mean IOP reduction from 22.32 mmHg to 14.05 mmHg, with 86% success rate in POAG patients and 81% in PACG patients, with no reported complications or visual acuity reductions.

    IRIX
  2. SEC EDGAR

    8-K filing — IRIDEX CORP (IRIX)

    Filed: 2026-09-02 AccNo: 0001193125-26-380229 Size: 173 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits

    IRIX